Ovid Therapeutics Accelerates Pipeline Progress with Regulatory Clearance and Significant Funding
In a major milestone, Ovid Therapeutics announced regulatory clearance for the first-ever oral KCC2 direct activator, OV4071, during its recent Q4 2025 conference call. This achievement marks significant progress in the company's pipeline, with all programs advancing on track to patient proof-of-concept studies.
According to Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics, "we've now announced that we've received regulatory clearance for the first-ever oral KCC2 direct activator," adding that this milestone was achieved a quarter earlier than expected due to the hard work of the company's team over the holidays.
In addition to the regulatory clearance, Ovid Therapeutics also announced significant funding through a PIPE financing led by Point72. This capital injection will enable the company to launch additional studies for its next-generation GABA aminotransferase inhibitor, OV329, and other programs in infantile spasms and seizures associated with tuberous sclerosis complex.
The funding, which includes additional capital from top shareholders such as Janus, RA, Bellevue, Affinity, Coastland, Eventide, Adage, and ADAR1, will provide Ovid Therapeutics with a cash runway well into 2029. If the company's Series A warrants are exercised, this could bring an additional $53 million in capital.
Ovid Therapeutics' pipeline is focused on controlling neural hyperexcitability through differentiated and universal mechanisms of action using small molecule programs. The company aims to develop gentler, better medicines for the brain, making them easier for patients to take.
The announcement has been met with excitement, as Ovid Therapeutics is poised to make significant progress and achieve potential readouts throughout this year and into 2027. With a strengthened pipeline and significant funding in place, the company is well-positioned for future growth and success.
